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Interactome-wide Analysis Identifies End-binding
Protein 1 as a Crucial Component for the
Speck-like Particle Formation of Activated
Absence in Melanoma 2 (AIM2) Inflammasomes*□S
Li-Jie Wang‡, Chia-Wei Hsu‡, Chiu-Chin Chen§, Ying Liang§, Lih-Chyang Chen§,
David M. Ojcius¶, Ngan-Ming Tsang**, Chuen Hsueh§‡‡, Chih-Ching Wu§§§¶¶,
and Yu-Sun Chang‡§¶¶
Inflammasomes are cytoplasmic receptors that can rec-
ognize intracellular pathogens or danger signals and are
critical for interleukin 1 production. Although several key
components of inflammasome activation have been iden-
tified, there has not been a systematic analysis of the
protein components found in the stimulated complex. In
this study, we used the isobaric tags for relative and
absolute quantification approach to systemically analyze
the interactomes of the NLRP3, AIM2, and RIG-I inflam-
masomes in nasopharyngeal carcinoma cells treated with
specific stimuli of these interactomes (H2O2, poly (dA:dT),
and EBV noncoding RNA, respectively). We identified a
number of proteins that appeared to be involved in the
interactomes and also could be precipitated with anti-
apoptosis-associated speck-like protein containing cas-
pase activation and recruitment domain antibodies after
stimulation. Among them, end binding protein 1 was an
interacting component in all three interactomes. Silencing
of end binding protein 1 expression by small interfering
RNA inhibited the activation of the three inflammasomes,
as indicated by reduced levels of interleukin 1 secretion.
We confirmed that end binding protein 1 directly inter-
acted with AIM2 and ASC in vitro and in vivo. Most impor-
tantly, fluorescence confocal microscopy showed that
end binding protein 1 was required for formation of the
speck-like particles that represent activation of the AIM2
inflammasome. In nasopharyngeal carcinoma tissues, im-
munohistochemical staining showed that end binding
protein 1 expression was elevated and significantly cor-
related with AIM2 and ASC expression in nasopharyngeal
carcinoma tumor cells. In sum, we profiled the interac-
tome components of three inflammasomes and show for
the first time that end binding protein 1 is crucial for the
speck-like particle formation that represents activated
inflammasomes. Molecular & Cellular Proteomics 11:
10.1074/mcp.M112.020594, 1230–1244, 2012.
Nasopharyngeal carcinoma (NPC)1 is a malignancy of the
head and the neck that is highly prevalent in Southern China
and Southeast Asia (1). Both environmental and genetic risk
factors are considered to be important for the development of
NPC (2, 3); among them, Epstein-Barr virus (EBV) infection of
the epithelium is the most important known factor (1). In
addition to the EBV-encoded oncoprotein-mediated blockade
of intracellular mechanisms in EBV-associated tumors (1),
chronic inflammation is considered to be an important onco-
genic factor in NPC (4). Interleukin 1 beta (IL-1), which is an
inflammatory cytokine that has oncogenic effects in many
tumors (5), can be detected in NPC tumor tissues (6, 7). IL-1
secretion is mediated by cytosolic protein complexes called
inflammasomes, which induce IL-1 secretion by activating
catalytic caspase 1 (8). However, no previous study has ex-
amined inflammasome components in NPC tumor cells or the
mechanisms of inflammasome regulation in NPC.
Inflammasomes are cytoplasmic receptors that act in innate
immunity to recognize intracellular pathogen-associated mo-
lecular pattern (PAMP) or danger signal-associated molecular
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pattern (DAMP). A number of inflammasomes have been iden-
tified in recent years (9), and they can be classified into
different subgroups according to their recognizing PAMP.
These groups include the NOD-like receptors (NLR), which
sense intracellular pathogens (e.g. bacteria, fungi, and para-
sites) and activate pro-caspase 1 with or without an adaptive
protein called apoptosis-associated speck-like protein con-
taining caspase activation and recruitment domain (ASC) (10).
Activated caspase 1 then induces IL-1 secretion through
direct cleavage of pro-IL-1 (8). Among the NLR family mem-
bers, the NLRP3 inflammasome recognizes both pathogens
and danger signals such as ATP or reactive oxygen species
(ROS) generation (11, 12). Members of the two other sub-
groups, absence in melanoma 2 (AIM2) and retinoic acid-
inducible gene I (RIG-I), sense cytoplasmic double-strand
DNA and 5-triphoshphate RNA, respectively, and then recruit
ASC to activate pro-caspase 1 (13, 14). Although inflam-
masomes are important for pathogen defense in immune
cells, recent studies have shown that inflammasomes also
participate in tumorigenesis in colon cancer and melanoma
(15–17). A previous report showed that EBV noncoding
RNAs (EBERs) are recognized by RIG-I and activate signal-
ing to induce type I IFN in EBV-infected B lymphocytes (18).
This report is consistent with our recent unpublished obser-
vation that RIG-I is activated by EBERs in NPC cells. We
additionally show that NLRP3 is triggered by tumor mi-
croenvironmental factors, such as ATP and ROS, and the
clinical drug cisplatin; AIM2 recognizes EBV genomic DNA
and is activated by irradiation in NPC cells. Although these
inflammasomes play important role in NPC, the regulation
and the interactome of these inflammasome complexes are
not fully understood.
On activation by PAMP or DAMP, the activated inflam-
masomes tend to aggregate in the cytosol as speck-like par-
ticles (13). Biochemical and cell biological data have indicated
that the core components of the inflammasome comprise the
receptor, ASC, and pro-caspase 1, but an increasing number
of proteins have been identified as interacting with these
complexes. For example, heat-shock protein 90 (HSP90) is
essential for the function of the NLRP3 and RIG-I inflam-
masomes (19, 20). NLRC5, another member of the NLR fam-
ily, is involved in the NLRP3 inflammasome and is required for
its activity (21). Rac1, a small Rho GTPase family member, is
reportedly required for NLRP3 inflammasome activation dur-
ing C. pneumoniae infection (22). The S. Typhimurium effec-
tor, SopE, activates caspase 1 through Rac1 activity (23),
whereas Yersinia bacteria prevent caspase 1 activation by
inhibiting Rac1 activity via the effector protein, YopE (24).
Notably, Rac1 regulates cytoskeletal rearrangement (25), sug-
gesting that cytoskeletal components may participate in in-
flammasome activation.
End-binding protein 1 (EB1), an adenomatous polyposis
coli (APC)-binding protein, regulates microtubule polymeriza-
tion by recruiting the plus-end tracking protein (TIP) com-
plex to the plus end of microtubules (26). The interaction of
EB1 and the TIP complex depends on the C-terminal (CT)
domain of EB1, whereas the calponin homology (CH) domain
of EB1 binds to the microtubule (26). Many studies have
shown that EB1 participates in different biological processes,
including mitosis, migration and signal transduction (27–29),
and also that it plays an oncogenic role in cancer by affecting
cell growth or migration (30, 31). However, although EB1 is
known to be a cytoskeletal component that is regulated by the
small GTPase, RhoA (28), its role in inflammasome activation
has not yet been explored.
Here, we used the isobaric tags for relative and absolute
quantification (iTRAQ) approach to systemically analyze the
interactomes of the NLRP3, AIM2, and RIG-I inflammasomes
in NPC cell lines treated with their specific stimuli, H2O2, poly
(dA:dT), and EBER, respectively. We characterized the inter-
actomes of the NLRP3, AIM2, and RIG-I inflammasomes in
NPC cells by proteomic analysis, and report for the first time
that EB1 can directly bind to the AIM2 inflammasome and is
essential for speck-like particle formation in NPC cells. Finally,
we suggest some possible mechanisms for EB1-associated
AIM2 inflammasome activation via microtubule polymeriza-
tion and RhoA activity.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—The anti-pro-caspase 1, anti-EB1 for
IHC, anti-RhoA, anti-tubulin, anti-GST and anti-His antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The
anti-Flag antibody was purchased from Sigma-Aldrich (St. Louis,
MO). The anti-ASC antibody for immunoprecipitation and Western
blot analysis was purchased from Calbiochem (Darmstadt, Germany).
The anti-ASC for immunohistochemistry (IHC) staining and anti-
caspase 1 (p20) were from Merck Millipore (Billerica, MA). The anti-
AIM2 antibody for Western blotting was purchased from Abnova
(Taipei City, Taiwan), whereas that for IHC staining was from Deci-
phergen Biotechnology (Cheshire, CT). The anti-RIG-I antibody was
from ENZO Life Sciences (Plymouth Meeting, PA). The anti-Rac1 and
anti-cdc42 antibodies for Western blotting and the anti-EB1 antibody
for Western blotting and immunofluorescence were purchased from
BD Transduction Laboratories (BD Biosciences, San Jose, CA). The
anti-FLAG M2 affinity gel, poly (dA:dT), LPS, PMA and nocodazole
were purchased from Sigma-Aldrich (St Louis, MO), the H2O2 was
purchased from Calbiochem (San Diego, CA), and the paclitaxel was
purchased from Bristol-Myers Squibb Co. (New York, NY). Protein G
Sepharose 4 Fast Flow, Glutathione Sepharose 4B, and Ni Sepharose
6 Fast Flow were all purchased from GE Healthcare. Cy3-labeled
plasmid DNA was purchased from Mirus Bio LLC (Madison, WI).
Plasmid Construction—The wild-type EB1 construct, domain-only
EB1 constructs, and the wild-type AIM2 construct were PCR ampli-
fied from HK1 cDNA and cloned into HindIII/BamHI-treated pFlag-
CMV2 vectors (Clontech Laboratories, Inc.). Wild-type ASC was PCR
amplified from HK1 cDNA and cloned into HindIII/BamHI-treated
pEGFP-N1 vectors (Clontech Laboratories, Inc.). Wild-type AIM2 was
cloned into HindIII/BamHI treated pDsRed-Monomer-C1 (a kind gift
from Dr. S.J. Lo; Chung Gung University, Taiwan). For GST pull-down
assays, wild type and domain-only EB1 were cloned into BamHI/NotI-
treated pGEX-4T2 (BD Biosciences). The wild type and domain-only
AIM2 and wild-type ASC were respectively cloned into NdeI/BamHI-
and NdeI/XhoI- treated pET-15b vectors (a kind gift from Dr. S.C. Hsu;
Chung Gung University, Taiwan). For AIM2 and PYD domain of AIM2-
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expressing HK1 cells, the AIM2 and PYD domain of AIM2 were cloned
into NheI/AscI treated pLKO-AS2-neo empty vectors (RNAi Core,
Taiwan). For ASC-expressing HK1 cells, the ASC was cloned into
AscI/EcoRI treated pLKO-AS2-neo empty vectors (RNAi Core,
Taiwan).
Cell Culture—NPC TW02 and HK1 cells were cultured as previ-
ously described (32, 33) and THP-1 cells were culture in Roswell Park
Memorial Institute medium (33). Lentiviruses were established follow-
ing the protocol of the RNAi Core of Taiwan (http://rnail.genmed.
sinica.edu.tw), and used to generate HK1 cells expressing human
ASC, wild-type AIM2, and the PYD domain of AIM2. The cells were
maintained with 500 g/ml G418 (Invitrogen, Carlsbad, CA). For
transfection assays, cells were transfected with poly (dA:dT) and
EBER using Lipofectamine 2000 (Invitrogen).
Immunoprecipitation of ASC Complexes—HK1/ASC cells were
treated with H2O2 (10 M) for 20 h, poly (dA:dT) for 6 h, or EBER for
6 h. Cell extracts (10 mg) were collected by radioimmunoprecipitation
assay (RIPA) buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 10 mM
MgCl2, 1 mM ethylenediamine tetraacetate, pH 8.0, 1% Nonidet P-40,
100 mM sodium fluoride, 1 mM phenylmethylenesulfonyl fluoride) and
immunoprecipitated with anti-ASC antibodies (10 g) for 24 h. The
samples were then precipitated with Protein G Sepharose 4 Fast Flow
for 2 h at 4 °C, and the immunoprecipitated products were collected
for iTRAQ analysis.
Preparation of Cell Extracts and Digestion of Immunoprecipitated
Products—Cell extracts were prepared as previously described (34).
Briefly, NPC cells were washed three times with 10 ml of PBS and
lysed in hypotonic buffer (10 mM Tris, pH 7.4, 1 mM EDTA, 1 mM
EGTA, 50 mM NaCl, 50 mM NaF, 20 mM Na4P2O7, 1 mM Na3VO4, 1 mM
PMSF, 1 mM benzamidine, 0.5 g/ml leupeptin, and 1% Triton-X100)
on ice for 15 min. The cell lysates of four samples were collected in
parallel and sonicated on ice, followed by centrifugation at 10,000 
g for 25 min at 4 °C. The resulting supernatants were used as the cell
extracts. Protein concentrations were determined using the bicin-
choninic acid protein assay reagent from Pierce (Rockford, IL). For
tryptic in-solution digestion, the immunoprecipitated products were
denatured with 8 M urea containing 50 mM triethylammonium bicar-
bonate (TEABC, Sigma-Aldrich), reduced with 10 mM Tris (2-carboxy-
ethyl)-phosphine (TCEP, Sigma-Aldrich) at 37 °C for 90 min, and then
alkylated with 10 mM methyl methanethiosulfonate (MMTS, Sigma-
Aldrich) at room temperature for 20 min. After desalting, the protein
mixtures were in-solution digested overnight at 37 °C with modified
sequencing grade trypsin (Promega, Madison, WI).
ITRAQ Reagent Labeling and Fractionation by Strong Cation Ex-
change Chromatography—The peptides were labeled with the iTRAQ
reagent (Applied Biosystems, Foster City, CA) according to the man-
ufacturer’s protocol. Briefly, one unit of label (defined as the amount
of reagent required to label 100 g of protein) was thawed and
reconstituted in 70 l ethanol. The peptide mixtures were reconsti-
tuted with 25 l iTRAQ dissolution buffer. Aliquots of iTRAQ 114, 115,
116, and 117 were combined with peptide mixtures from the immu-
noprecipitated products of untreated HK1 cells, HK1 cells treated
with EBER, H2O2, and poly (dA:dT), respectively, and incubated at
room temperature for 1 h. The peptide mixtures were then pooled and
dried by vacuum centrifugation. Each dried peptide mixture was
reconstituted and acidified with 0.5 ml buffer A (0.1% formic acid and
25% acetonitrile, pH 2.5) and subjected to fractionation by SCX
chromatography using the Ettan MDLC system (GE Healthcare, Tai-
pei, Taiwan). The iTRAQ-labeled peptides were loaded onto a 2.1
mm  250 mm BioBasic SCX column with a 5-m particle size and a
300-m pore size (Thermo Electron, San Jose, CA). The peptides
were eluted at a flow rate of 100 l/min with the following gradient:
0–10% buffer B (300 mM NH4Cl, 0.1% formic acid and 25% aceto-
nitrile, pH 2.5) for 20 min, 10–20% buffer B for 35 min, 20–50% buffer
B for 15 min, and 50–100% buffer B for 10 min. The elution was
monitored by absorbance at 220 nm, and fractions were collected
every 1 min. Each fraction was vacuum dried, resuspended in 0.1%
formic acid (20 l), and subjected to desalting and concentration
using a Zip-tip packed in-house with C18 resin (5–20 m, LiChroprep
RP-18; Merck).
Liquid Chromatography-electrospray Ionization-tandem MS (LC-
ESI MS/MS) Analysis by LTQ-OrbitrapPQD—For analysis of the
iTRAQ-labeled peptide mixtures, each peptide fraction was reconsti-
tuted in HPLC buffer A (0.1% formic acid), loaded across a trap
column (Zorbax 300SB-C18, 0.3  5 mm; Agilent Technologies,
Wilmington, DE) at a flow rate of 0.2 l/min in HPLC buffer A, and
separated on a resolving 10-cm analytical C18 column (inner diameter,
75 m; tip, 15-m; New Objective, Woburn, MA). The peptides were
eluted at a flow rate of 0.25 l/min using the following linear gradient:
2–30% HPLC buffer B (99.9% acetonitrile containing 0.1% formic
acid) for 63 min, 30–45% buffer B for 5 min, and 45–95% buffer B for
2 min. The LC setup was coupled on-line to an LTQ-Orbitrap Discov-
ery system (Thermo Fisher, San Jose, CA) operated using the Xcalibur
2.0 software (Thermo Fisher). Intact peptides were detected in the
Orbitrap at a resolution of 30,000. Internal calibration was performed
using the ion signal of (Si(CH3)2O)6H at m/z 445.120025 as a lock
mass (35). Peptides were selected for MS/MS using the PQD oper-
ating mode with a normalized collision energy setting of 27%, and
fragment ions were detected in the LTQ system (36, 37). We used a
data-dependent procedure that alternated between one MS scan
followed by three MS/MS scans for the three most abundant precur-
sor ions in the MS survey scan. The m/z values selected for MS/MS
were dynamically excluded for 180 s. The electrospray voltage ap-
plied was 1.8 kV. Both MS and MS/MS spectra were acquired using
the 4 microscan setting with a maximum fill-time of 1000 and 100 ms
for MS and MS/MS, respectively. Automatic gain control was used to
prevent over-filling of the ion trap, and 5 104 ions were accumulated
in the ion trap for generation of the PQD spectra. For MS scans, the
m/z scan range was set at 350 to 2000 Da.
Database Searching and Data Analysis—All MS/MS samples were
analyzed using the MASCOT search algorithm (Version 2.1, Matrix
Science, London, UK). Mascot was used to search the SwissProt
database (released Jun 15, 2010, selected for Homo sapiens, 20367
entries), assuming trypsin as the digestion enzyme. For protein iden-
tification, the following settings were used: 10 ppm mass tolerance
was permitted for intact peptide masses; 0.5 Da was allowed for
PQD fragment ions; one missed cleavage was allowed from the
trypsin digest; oxidized methionine (16 Da) was accepted as a
potential variable modification; and iTRAQ (Nterminal, 144 Da),
iTRAQ (K, 144 Da) and MMTS (C, 46 Da) were taken as the fixed
modifications.
The MASCOT search results for each SCX elution were further
processed using the Trans-Proteomic Pipeline (TPP, version 4.0),
which includes the programs PeptideProphet, ProteinProphet, and
Libra (38–40). PeptideProphet is a peptide probability score program
that aids in the assignment of peptide MS spectra (41); it assigns
peptides to a unique protein or protein family, allows filtering of
large-scale data sets, and predicts the sensitivity and false-positive
identification error rates (42). We used a ProteinProphet probability
score of  0.90 to ensure an overall false positive rate below 1%,
and excluded proteins identified with only a single peptide hit.
Protein quantification was achieved with the Libra program (38, 39,
43), using the default setting. A weighted average of the peptide
iTRAQ ratios per protein was used to quantify the protein. The
following were excluded: peptides with iTRAQ reporter ion intensi-
ties lower than 30, peptides with an iTRAQ ratio beyond twofold
deviation from the mean ratio, and proteins with  2 spectra.
Proteins with iTRAQ ratios below the low range (mean ratio - 0.2)
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were considered to be decreased in the ASC-associated protein
complexes, whereas those above the high range (mean ratio  0.2)
were considered to be increased in the protein complexes. Infor-
mation on PeptideProphet, ProteinProphet, and Libra can be found
on the website for the Institute for Systems Biology of the Seattle
Proteome Center (http://www.proteomecenter.org/).
RNA Interference—SMARTpool reagents, including four 21-bp
RNA duplexes targeting each of RIG-I, RhoA and cdc42 were pur-
chased from Dharmacon (Lafayette, CO). Stealth RNAi reagents, in-
cluding three 25-bp RNA duplexes targeting each of NLRP3, AIM2,
EB1, and Rac1 were purchased from Invitrogen (Carlsbad, CA). The
negative-control siRNA was synthesized by Research Biolabs (Sin-
gapore). Cells were transfected with 75 pmol dsRNA duplexes using
Lipofectamine 2000 according to the manufacturer’s instructions.
After 6 h incubation, the dsRNA complexes were removed and the
cells were re-plated in 5 ml fresh medium. The oligonucleotide se-
quences of the dsRNA duplexes are presented in supplementary
Table S3.
In Vitro Synthesis of EBER1—In this study, we used EBER1 as the
EBER stimulation. EBER1 cDNAs were generated from C666–1 NPC
cells by reverse transcription (primer: 5-CCCTTTACATGTTGTGGGT-
GCAAAACTAGCCA) and cloned downstream of the T7 promoter in
the pGEMTeasy vector (Promega) to generate pGEMT-EBER1. T7
promoter-fused EBER1 was amplified by PCR (primers: EBER1, 5-
TGTAATACGACTCACTATAGGGAGGACCTACGCTGCCCTAGAG-
GTT and 5-AAAACATGCGGACCACCAGCTGGTACTTG), and 1 g
of purified PCR product was used for in vitro transcription, which was
performed for 4 h according to the manufacturer’s instructions (Epi-
center, Madison, WI). Purified EBER1 (3 g) treated with or without
RNase A was checked on a 6% denaturing polyacrylamide gel and by
RT-PCR.
IL-1 ELISA—Cell culture supernatants were assayed for human
IL-1 using the Human IL-1 ELISA Ready-SET-Go Kit (eBioscience,
San Diego, CA) according to the manufacturer’s instructions.
Quantitative RT-PCR—Quantitative RT-PCR analysis was per-
formed as previously described (34). The primer sequences for
NLRP3 were 5 TCTGTGTGTGGGACTGAAGCA (sense) and 5 TACT-
GATGCAAGATCCTGACAACA (antisense). The gene expression re-
sults were normalized with regard to the expression of GADPH.
GST Pull-down Assays—All recombinant proteins were expressed
in BL21 (DE3) E. coli. Glutathione-Sepharose beads complexed with
GST, wild-type GST-EB1 and domain-only GST-EB1 were respec-
tively incubated with purified wild-type His-AIM2 or wild-type His-
ASC in RIPA buffer for 24 h at 4 °C. The Ni-Sepharose beads com-
plexed with His, wild-type His-AIM2 and domain-only His-AIM2 were
respectively incubated with purified wild-type GST-EB1 in RIPA buffer
for 24 h at 4 °C. After six washes in RIPA buffer, all samples were
collected for Western blot analysis.
Western Blot Analysis—Whole-cell extracts were homogenized
and lysed in a buffer containing 50 mM Tris-Cl (pH 7.5), 150 mM NaCl,
10 mM MgCl2, 1 mM ethylenediamine tetraacetate (pH 8.0), 1% Non-
idet P-40, 100 mM sodium fluoride, 1 mM phenylmethylenesulfonyl
fluoride, and 2 l/ml protease inhibitor mixture (Sigma-Aldrich). Pro-
tein concentrations were determined using a protein assay reagent
(Bio-Rad), and equal amounts of proteins (30–50 g/lane) were re-
solved on a 12% SDS-polyacrylamide gel. The proteins were then
electro-transferred onto nitrocellulose (NC) membranes (Amersham
Biosciences). The blots were blocked with 5% nonfat powdered milk
in TBS, incubated overnight with the respective primary antibodies at
4 °C, and then incubated with HRP-conjugated rabbit/goat/mouse
anti-IgG (Invitrogen) for 1 h at room temperature. Protein bands were
detected by enhanced chemiluminescence (Pierce ECL, Thermo Sci-
entific) on Fuji SuperRx films.
Immunofluorescence Microscopy—Cells grown on polylysine-
coated coverslips were fixed with 3.7% formaldehyde, permeabilized,
and blocked with 0.1% saponin containing 1% BSA for 20 min. The
coverslips were incubated with the indicated primary antibodies for
2 h, and then with the appropriate fluorophore-conjugated secondary
antibodies for 1 h at room temperature. Nuclei were stained with
4-6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). All coverslides
were mounted with the VECTASHEILD reagent (Vector Laboratories
Inc., CA, USA) and visualized by confocal microscopy using a ZEISS
LSM510 META laser scanning microscope (Carl Zeiss, Germany) with
a 63  1.32 NA oil immersion objective.
Clinical Specimens—The retrospective cohort comprised 95 NPC
patients who were admitted to Chang Gung Memorial Hospital
(CGMH) at Lin-Kou from 1990 to 2000. Clinical stage was defined
according to the 2002 cancer staging system revised by the American
Joint Committee on Cancer. These included 32 stage-I 26 stage-II, 20
stage-III, and 17 stage-IV patients comprising 70 men and 25 women
ranging from 14 to 78 years of age (mean age 46). Histological typing
was done according to the World Health Organization (WHO) classi-
fication criteria (44). This study was reviewed and approved by the
institutional review board and ethics committee of CGMH. Informed
consent was obtained from all patients.
Immunohistochemistry—Samples of NPC and adjacent normal na-
sopharyngeal tissues were obtained from patients undergoing sur-
gery, and were frozen immediately after surgical resection. Immuno-
histochemistry was performed according to the previously described
procedures (45, 46). Staining for AIM2, ASC, and EB1 was carried out
using the Envision-kit (DAKO, Carpinteria, CA). Briefly, the sections
were deparaffinized with xylene, dehydrated with ethanol, and then
heated in 0.01 M citrate buffer (pH 6.0). Endogenous peroxidase
activities were inactivated in 3% H2O2 for 10 min at room tempera-
ture, and the sections were blocked with 3% normal goat serum in 0.2
M PBS (pH 7.4). Samples were then incubated with specific antibody
for 2 h at room temperature. Secondary antibody-coated polymer
peroxidase complexes (DAKO) were then applied for 30 min at room
temperature, followed by treatment with substrate/chromogen
(DAKO) and a further incubation for 5–10 min at room temperature.
The slides were counterstained with hematoxylin, and protein expres-
sion was assessed by quantitative scoring of the staining intensity
and the proportion of positively stained cells. The staining intensity
was graded as 0, 1, 2, or 3 to indicate undetectable, weak, moderate,
and strong staining, respectively. These scores were multiplied by the
percentage of cells that showed positive staining. The resulting
scores, which were taken as reflecting protein expression, were used
to classify the specimens/patients into two groups: “high-level” ex-
pression (ASC scores  120, AIM2 scores  140, EB1 scores  60)
and “low-level” expression (ASC scores  120, AIM2 scores  140,
EB1 scores  60). ASC-, AIM2-, EB1-positive tumor cells in repre-
sentative microscopic fields were scored independently by two ex-
perienced pathologists.
Statistical Analysis—Statistical analyses were performed using the
SPSS 13.0 statistical software package. Expression correlations were
evaluated using the Chi-Square test. The cut-off values to define high
intensity of IHC staining in tumor cells were determined from Receiver
Operating Characteristics curve analysis.
RESULTS
Identification of Protein Components Involved in Inflam-
masome Complexes of NPC Cells by iTRAQ-LC-MS/MS Anal-
ysis—Many reports have shown that inflammasomes are in-
volved in tumor development (15, 47, 48). In NPC, we found
that NLRP3, AIM2, and RIG-I inflammasomes were up-regu-
lated in an NPC Affymetrix microarray database (supplemen-
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tal Fig. S1). These three inflammasomes require the adaptive
protein, ASC, to activate pro-caspase 1. Here, in an effort to
identify novel protein components of activated inflammasome
complexes in NPC cells, we conducted immunoprecipitation
of ASC complexes from ASC-expressing HK1 (HK1/ASC)
cells untreated or treated with EBER, H2O2, and poly (dA:dT)
using total cell extract, followed by iTRAQ-based quantitative
proteomic analysis (Fig. 1A) and two-dimensional liquid chro-
matography-mass spectrometry (LC-MS/MS). The two-di-
mensional fractionation of the labeled peptides involved an
offline SCX-based separation followed by an online reverse
phase fractionation (Fig. 1A). The resulting MS/MS spectra
were analyzed using the SwissProt database (released Jun
15, 2010, selected for Homo sapiens, 20367 entries) with the
MASCOT algorithm. The search results were further evaluated
using the open-source TPP software (version 4.0) with strin-
gent criteria regarding protein probability (0.90) and at least
two peptide hits for each identified protein. The false discov-
ery rate (FDR) of protein detection was empirically determined
by searching the dataset against a random SwissProt data-
base using the same search parameters and TPP cutoffs. The
estimated FDR of 0.9% was calculated as the number of
reverse proteins divided by the number of forward proteins.
Using this approach, we identified 172 nonredundant pro-
teins in the inflammasome complexes of HK1/ASC cells (sup-
plementary Table S1). After the removal of proteins with fewer
than three spectra, we obtained 131 proteins that we consid-
ered quantifiable complex components (supplementary Table
S2). Among them, comparing with untreated control, we de-
tected 8, 13, and 22 proteins with increase levels and 10, 11,
and 31 proteins with decrease levels in inflammasome com-
plexes from HK1/ASC cells treated with H2O2, poly (dA:dT),
and EBER, respectively (Table I; Fig. 1B). Among the 22
proteins associated with EBER treatment (i.e. RIG-I inflam-
masome activation), six belong to the heterogeneous nuclear
ribonucleoprotein family. Consistent with previous reports
(19, 20), we also identified heat shock protein 90 (HSP90)
(supplementary Table S1) as being involved in the NLRP3 and
RIG-I inflammasomes, respectively. Notably, we found three
proteins that were elevated after all treatments: (1) dihydroli-
poamide S-succinyltransferase (DLST), which catalyzes the
overall conversion of 2-oxoglutarate to succinyl-CoA and CO
(49); (2) end-binding protein 1 (EB1), which is involved in
microtubule polymerization, mitosis, and migration (26); (3)
and the 60S ribosomal protein, L34 (RL34), which participates
in translation (50). Our findings suggest that these proteins
may be recruited to the inflammasome complexes upon stim-
ulation. Three other proteins were found to be down-regulated
after all treatments: (1) structural maintenance of chromo-
somes protein 3 (SMC3), which is involved in mitosis (51); (2)
thrombospondin-1 (TSB1), which participates in tumor devel-
opment (52); (3) and titin (TTN), which regulates the function of
muscle cells (53). These proteins may play negative regulatory
roles in inflammasome activation. To investigate the compo-
nents of the activated inflammasome, we herein focused on
the up-regulated proteins identified in our iTRAQ assay.
Biological Process Network Analysis of iTRAQ Candidates
by Metacore—According to previous reports, cytoskeletal re-
arrangement may be involved in inflammasome activation (22,
54). To evaluate the candidates identified by our iTRAQ anal-
ysis, we used the Metacore software to analyze the process
networks that use these candidates. Our results indicated that
proteins significantly involved in the translation-related, cyto-
FIG. 1. Differentially expressed proteins in the activated inflam-
masome complexes of HK1/ASC cells, as assessed by iTRAQ. A,
A flow chart showing our iTRAQ-based proteomic analysis of inflam-
masome complexes. B, The numbers of proteins found to be elevated
or decreased after H2O2, poly (dA:dT) or EBER treatment, as as-
sessed by iTRAQ.
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skeleton-related and protein folding categories were differen-
tially present in the 131 quantified proteins (Table II). Further-
more, Metacore analysis of the 67 level-changed candidates
revealed the potential involvement of mitosis, microtubule
regulation, cell adhesion regulation and mRNA processing
(Table II). Among the candidates that were preferentially present
in all of threes inflammasomes, EB1 (encoded by MAPRE1),
which participates in microtubule regulation and mitosis (Table
II; supplemental Fig. S2) and was up-regulated in response to all
three treatments, was selected for further study.
EB1 is a Novel Component of Inflammasome Complexes
and is Important for their Activation in NPC Cells—To deter-
mine if EB1 is involved in the stimulation-induced formation of
the inflammasome complex, we first carried out co-immuno-
precipitation assays using extracts of HK1/ASC cells treated
with H2O2, poly (dA:dT) or EBER, which activate NLRP3, AIM2
and RIG-I, respectively. As shown in Fig. 2A, immunoprecipi-
tation with an anti-ASC antibody showed that ASC-associ-
ated EB1 was elevated in cells treated with all three inflam-
masome-specific stimuli. We then tested whether EB1 is
involved in the activation of inflammasomes by using small
interfering RNA (siRNA) to decrease the expression of EB1,
NLRP3, AIM2, or RIG-I (supplemental Fig. S3). The resulting
knockdown cells were treated with the corresponding stimuli,
and ELISA was used to measure the levels of the cytokine,
IL-1, in the culture media. As shown in Fig. 2B, the induction
of IL-1 by H2O2 was significantly reduced in cells treated
with si-EB1 and si-NLRP3, but not si-Control. Furthermore,
the activated caspase 1 (p20), as another indicator for inflam-
masome activation, was also decreased after knockdown
NLRP3 or EB1, comparing with si-Control. Similar inhibitions
of IL-1 secretion and decrease of activated caspase 1 were
detected in cells transfected with si-EB1 or si-AIM2 and sub-
sequently treated with poly (dA:dT) (Fig. 2C), and in cells
transfected with si-EB1 or si-RIG-I and subsequently treated
with EBER (Fig. 2D). Together, these results suggest that EB1
is a common component present in the NLRP3, AIM2, and
RIG-I inflammasome complexes, and that it is required for
their activation. Among the three inflammasomes examined,
the knockdown effect of si-EB1 was more profound for AIM2
inflammasome activation in response to poly (dA:dT) treat-
ment. Thus, the following studies were performed using the
AIM2 inflammasome.
EB1 is a 30-kDa, 268-amino acid microtubule-binding pro-
tein; its amino terminus contains a calponin homology (CH)
domain, which is found in many proteins involved in microtu-
bule binding, whereas its carboxyl terminus contains a C-ter-
minal (CT) dimerization domain that is required to recruit the
TIP complex during microtubule polymerization (25). Next,
we evaluated whether EB1 physically associates with the
inflammasome complex by co-immunoprecipitation assays of
AIM2 and ASC. NPC TW02 cells were transfected with Flag-
tagged EB1 (Flag-EB1) and stimulated with poly (dA:dT). Cell
extracts were precipitated with anti-Flag antibodies, and en-
dogenous AIM2 and ASC were detected by specific antibod-
ies. As shown in Fig. 3A, AIM2 and ASC were detected more
highly in immunoprecipitates from poly (dA:dT)-treated cell
extracts compared with those from untreated cells. Similarly,
more EB1 and ASC proteins were detected in cells trans-
fected with Flag-AIM2 and treated with poly (dA:dT)
compared with controls (Fig. 3B). Furthermore, AIM2 was
preferentially precipitated with anti-ASC antibodies in poly
(dA:dT)-treated cells, and more EB1 was detected in treated
cell extracts than in untreated controls (Fig. 3C). To investi-
gate the time course of the association of EB1 with AIM2
inflammasome, we transfected flag-AIM2 in NPC TW02 cells
and then precipitated AIM2 complex by anti-flag antibodies at
indicated time points. As shown in supplemental Fig. S4, the
TABLE II
Metacore process network analysis of quantificated and level changed candidates in inflammasome complexes
Quantificated candidates (n  131)
GeneGo process network p value
Translation_Translation initiation 1.03E-32
Translation_Elongation-Termination 1.71E-31
Cytoskeleton_Spindle microtubules 1.20E-03
Protein folding_Protein folding nucleus 1.70E-03
Level changed candidates (n  67)
GeneGo process network p value Candidates
Translation_Translation initiation 5.01E-11 RPL10, RPL13, RPL17, RPL18, RPL34, and RPL5
RPS11, RPS23, RPS27A, RPS4X, RPS7 and RPS9
Translation_Elongation-Termination 2.85E-10 RPL10, RPL13, RPL17, RPL18, RPL34, and RPL5
RPS11, RPS23, RPS27A, RPS4X, RPS7 and RPS9
Cytoskeleton_Spindle microtubules 2.56E-05 DYNC1H1, RAN, SMC3, TCP1 and TUBB
Cell cycle_Mitosis 8.90E-05 DYNC1H1, EB1, H1FX, RAN, RPS27A, SMC3, and TUBB
Cell adhesion_Integrin-mediated cell-matrix
adhesion
3.06E-04 CAV1, FN1, MYH9 and TSC1
Cytoskeleton_Cytoplasmic microtubules 3.17E-04 DYNC1H1, EB1, TCP1, and TUBB
Transcription_mRNA processing 1.80E-03 HNRNPA1, HNRNPA2B1, HNRNPA3, HNRNPD,
HNRNPH1, HNRNPU, and SFPQ
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EB1 and ASC were associated with the ectopically expressed
flag-AIM2 without poly (dA:dT) stimulation. An enhanced as-
sociation was detected at 2 h and reached plateau at 4–6h
after poly (dA:dT) treatment. Together, these results suggest
that EB1 may be recruited to the AIM2 inflammasome in
response to poly (dA:dT) stimulation.
EB1 Directly Interacts with AIM2—To dissect the domains
of EB1 responsible for its interaction with the AIM2 inflam-
FIG. 2. EB1 is involved in inflam-
masome complexes and is required
for their activity. A, Pull-down assays of
inflammasome complexes from cells
treated with NLRP3-, AIM2-, or RIG-I-
specific stimuli. Complexes were immu-
noprecipitated from HK1/ASC cells us-
ing anti-ASC antibodies, and EB1 levels
were detected with a specific antibody.
The amount of ASC was used as the
pull-down control. B, HK1 cells were
pretreated with control, NLRP3, or EB1
siRNA for 48 h and then treated with
H2O2 (10 M). After 24 h, media were
collected for IL-1 ELISA. C, HK1 cells
were pretreated with control, AIM2, or
EB1 siRNA for 48 h and treated with poly
(dA:dT) for 2 h. After a further incubation
for 10 h, media were collected for IL-1
ELISA. D, HK1 cells were prepared as
described in (C), but treated with EBER
instead of poly (dA:dT). Cell extracts
were collected, and then indicated mol-
ecules were detected by specific anti-
bodies. Symbols: *, p  0.05 and **, p 
0.01. The results are presented as the
means  S.D. of three experiments.
FIG. 3. EB1 associates with the AIM2 inflammasome after poly (dA:dT) treatment of NPC TW02 cells. A, NPC TW02 cells were
transfected with flag-EB1 for 48 h, treated with/without poly (dA:dT) for 2 h, and then further incubated for 4 h. Cell extracts were collected
and subjected to immunoprecipitation with an anti-Flag matrix, and Western blotting of the indicated proteins was performed using specific
antibodies. Flag-EB1 was detected using an anti-Flag antibody. B, NPC TW02 cells were transfected with Flag-AIM2 for 48 h, treated
with/without poly (dA:dT) for 2 h, and incubated for an additional 4 h. Cell extracts were collected and subjected to immunoprecipitation using
an anti-Flag matrix. The indicated proteins were detected by Western blotting. Flag-AIM2 was detected using an anti-Flag antibody. C, NPC
TW02 cells were transfected with GFP-ASC for 48 h, treated with/without poly (dA:dT) for 2 h, and further incubated for 4 h. Cell extracts were
collected and subjected to immunoprecipitation using anti-ASC antibodies. The indicated proteins were detected by Western blotting.
GFP-ASC was detected using an anti-GFP antibody.
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masome, we generated a series of Flag-tagged EB1 CH- and
CT domain-specific constructs (EB1-CH and EB1-CT in Fig.
4A) and examined their associations with AIM2 in response to
poly (dA:dT) treatment of NPC TW02 cells. Cells were indi-
vidually transfected with the empty vector, WT and domain-
specific EB1 constructs, treated with poly (dA:dT), and then
subjected to co-immunoprecipitation assays. As shown in
Fig. 4A, EB1-WT showed a strong association with AIM2
(5.7-fold increase), comparing with vector control. Both the
CH and CT domains could interact with AIM2, although
EB1-CT (3.3-fold) showed a slightly stronger interaction
than EB1-CH (2.4-fold). To investigate whether AIM2 inter-
acts with EB1 in a reciprocal manner, we conducted co-
immunoprecipitation assays using an anti-Flag matrix to
precipitate EB1 from lysates of HK1 cells stably expressing
Flag-AIM2-WT or Flag-AIM2-PYD, with or without poly (dA:
dT) treatment. The pyrin domain of AIM2 (AIM2-PYD), which
interacts with ASC to activate pro-caspase 1, interacted
with EB1 both with/without stimulation (3.9- and 4.1-fold),
whereas for the AIM2-WT binding was enhanced (2.7-fold
increase) by the treatment (Fig. 4B). We then tested the
direct binding between AIM2 and EB1 using GST pull-down
FIG. 4. EB1 directly interacts with AIM2 in vitro. A, NPC TW02 cells were transfected with empty vector or vectors encoding Flag-EB1-WT,
Flag-EB1-CH, or Flag-EB1-CT. After 48 h, the cells were treated with poly (dA:dT) for 2 h and incubated for 4 h, and then harvested for
immunoprecipitation using an anti-Flag matrix. The levels of AIM2 were assessed by Western blotting after immunoprecipitation. The
fold-change numbers were obtained from three independent experiments. B, HK1 cells stably expressing Flag-AIM2-WT or Flag-AIM2-PYD
(introduced by lentiviral infection) were treated with or without poly (dA:dT) and subjected to immunoprecipitation using an anti-Flag matrix. The
levels of EB1 were assessed by Western blotting. C, Purified GST, GST-EB1-WT, GST-EB1-CH, and GST-EB1-CT fusion proteins were
immobilized on glutathione agarose, and then separately incubated with purified His-AIM2-WT fusion proteins for 24 h. The bound proteins
were washed, and then analyzed by Western blotting with an anti-His antibody. The fold-change numbers were derived from three independent
experiments. The amounts of GST fusion proteins were assessed by Coomassie blue staining. D, Purified His-AIM2-WT or His-AIM2-HIN were
immobilized on Ni-charged agarose, and then incubated with purified GST-EB1-WT for 24 h. The bound proteins were washed, and then
analyzed by Western blotting with an anti-GST antibody. The fold-change numbers were obtained from three independent experiments. The
amount of His fusion proteins were assessed by Coomassie blue staining.
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assays. As shown in Fig. 4C, GST-EB1-WT pulled down
significantly more purified His-AIM2 following poly (dA:dT)
treatment (12.7-fold increase), whereas GST-EB1-CH and
GST-EB1-CT pulled down purified His-AIM2 in the absence
(5.3- and 4.7-fold) and presence (5.8-fold and 3.6-fold) of
poly (dA:dT). These results suggest that that the interaction
of EB1 and AIM2 is affected by double-strand DNA stimu-
lation. The direct binding of EB1 with purified His-ASC was
further confirmed by using GST-EB1-WT and purified His-
ASC in pull down assay, as our results showed that GST-
EB1-CT specifically bound to His-ASC, whereas GST-
EB1-CH did not (supplemental Fig. S5). Furthermore,
reciprocal immunoprecipitation experiments also supported
the direct interaction between EB1 and AIM2. As shown in
Fig. 4D, His-AIM2-WT pulled down twofold more GST-EB1
after poly (dA:dT) treatment. Although the HIN domain of
AIM2 (His-AIM2-HIN), which recognizes intracellular DNA,
interacted strongly with GST-EB1 in the presence (6.6-fold)
or absence (8.3-fold) of stimulation. Together, these results
indicate that EB1 directly interacts with both AIM2 and ASC,
and that these EB1-AIM2 and EB1-ASC interactions are
likely to be important for AIM2 inflammasome activation.
EB1 Colocalizes with AIM2 and ASC and is Required for
AIM2 Speck-like Particle Formation in NPC Cells—Inflam-
masome activation triggers speck-like particle formation in
the cytosol, where the complexes are formed (13). To confirm
that the activated AIM2 inflammasome contains EB1 in addi-
tion to AIM2 and ASC, we examined if these proteins colo-
calized in activated speck-like particles. We transfected com-
mercial Cy3-labeled plasmid DNA into NPC TW02 cells to
activate the AIM2 inflammasome, and then investigated
whether the labeled DNA and EB1 colocalized with endoge-
nous AIM2 by fluorescence confocal microscopy. As shown in
Fig. 5A, EB1 did indeed colocalize with Cy3-labeled plasmid
DNA in the cytosolic speck-like particles. Similarly, EB1 co-
localized with AIM2 or ASC in speck-like particles following
poly (dA:dT) treatment (Fig. 5B and 5C). We then tested
whether EB1 affected speck formation by using siRNA to
knock down EB1 in NPC TW02 cells, transfecting the cells
with GFP-AIM2 or DsRed-ASC, and using immunofluores-
cence confocal microscopy to examine complex formation
with or without poly (dA:dT) treatment. The formation of
speck-like particles of the AIM2 inflammasome was indeed
disrupted when cells were treated with EB1-specific siRNA
(Fig. 5D), indicating that EB1 is involved in speck-like particle
formation. Collectively, these findings indicate that EB1 is
required for AIM2 inflammasome complex formation, which is
an important process in the activation of procaspase 1.
The Expression of EB1 is Statistically Correlated with that of
AIM2 and ASC in NPC Patients—To examine whether EB1
participates in AIM2 inflammasome activation in vivo, and to
assess the potential oncogenic role of the EB1 over-expres-
sion observed in various cancers (31, 55–57), we investigated
the correlation of EB1 expression with AIM2 and ASC in NPC
biopsy tissues. Immunohistochemical staining showed that
EB1, AIM2, and ASC were highly expressed in NPC tumor
tissues (Fig. 6). A correlational study carried out in 95 NPC
biopsy samples showed that high expression of EB1 was
statistically correlated with high expression of AIM2 (p 0.05)
and ASC (p  0.01) (Table III). Thus, it appears likely that EB1
plays a physiologically relevant role in NPC.
DISCUSSION
Inflammasome activation is believed to play a role in tumor-
igenesis (17, 47), but the detailed molecular basis of inflam-
masome activation and its role in malignancy is not yet fully
understood. Here, we used iTRAQ-based proteomic analysis
to characterize the interactomes of the NLRP3, AIM2, and
RIG-I inflammasomes. ASC pull-down experiments demon-
strated that a novel component, EB1, was preferentially re-
cruited to the activated NLRP3, AIM2, and RIG-I inflam-
masomes stimulated with H2O2, poly (dA:dT) and EBER,
respectively (Table I and Fig. 2A). Metacore network analysis
showed that many of the differentially expressed candidates
were involved in microtubule-associated processes (Table II);
among them, EB1 was elevated in response to all three stim-
uli. We confirmed the direct interaction of EB1 with AIM2 and
ASC in NPC cells and in vitro. Knockdown of EB1 expression
abolished inflammasome-induced IL-1 secretion and dis-
rupted the formation of speck-like particles. In NPC tissue
samples, we further verified the expression of EB1 and its
correlation with AIM2 and ASC, not only providing support for
the physiological relevance of this mechanism but also linking
EB1 to NPC. Thus, our findings suggest that EB1 serves as a
crucial molecule for inflammasome assembly, extending our
knowledge of the inflammasome complex beyond its core
machinery.
The systematic iTRAQ analysis of proteins in three inde-
pendent activated inflammasomes proved to be a powerful
approach to search for novel components in these biological
interactomes. Unlike previous studies that proteomic
screened the downstream targets of activated caspase 1 (58,
59), we herein used proteomics to identify proteins that par-
ticipate in the assembly of activated inflammasome com-
plexes. We found that many nucleotide-binding proteins of
the hnRNP family appear to be involved in the responses to
poly (dA:dT) or EBER (Table I), suggesting that these proteins
may be involved in the association of nucleic-acid binding
during inflammasome activation. The hnRNP family proteins
are important for mRNA processing and mRNA stability (34),
and are considered to have oncogenic potential in many
cancers, including NPC (44). Our findings provide evidence
that these proteins may play an additional role in the activa-
tion of cytoplasmic nucleotide-sensing inflammasomes (AIM2
and RIG-I). Consistent with a previous report that many mi-
crotubule-associated proteins, including EB1, were up-regu-
lated during macrophage activation (60), our iTRAQ analysis
identified EB1 and numerous other microtubule-associated
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proteins that may participate in inflammasome activation (sup-
plemental Table 1). We also identified an association between
the activated NLRP3 inflammasome and HSP90, which was
previously reported to stabilize the NLRP3 inflammasome prior
to activation (61). Thus, this protein appears to also play an
important role in the pre-activated inflammasome. Notably,
most of the candidate proteins differed between H2O2-stimu-
lated NLRP3 inflammasomes and the other two stimulated in-
flammasome types (Table I). Thus, it could prove interesting to
re-examine the NLRP3 inflammasome using alternative ap-
proaches, such as immunoprecipitation with anti-NLRP3 anti-
bodies followed by direct mass spectrometric identification.
Here, we showed that EB1 directly interacted with AIM2
and ASC, both in NPC cells and in vitro. It has been reported
FIG. 5. EB1 colocalizes with the
AIM2 inflammasome and is required
for speck-like particle formation in
NPC TW02 cells. A, Cells were treated
with or without Cy3-labeled plasmids for
2 h, and were further incubated for 4 h.
Cells were fixed and were stained with
an anti-EB1 antibody, and the colocal-
ization of Cy3-labled plasmids and EB1
was observed by confocal immunoflu-
orescence microscopy. B, and C, Cells
were transfected with DsRed-AIM2 or
DsRed-ASC for 48 h, treated with poly
(dA:dT) for 2 h, and further incubated
for 4 h. The cells were then fixed and
stained with an anti-EB1 antibody, and
the colocalization of EB1 with DsRed-
AIM2 or DsRed-ASC was observed by
confocal immunofluorescence micros-
copy. D, NPC TW02 cells expressing
control siRNA or EB1 siRNA were co-
transfected with GFP-AIM2 and DsRed-
ASC for 48 h, treated with or without
poly (dA:dT) for 2 h, further incubated for
4 h, and then fixed. The colocalization of
GFP-AIM2 and DsRed-ASC was ob-
served by confocal fluorescence micros-
copy. Scale bar  20 m.
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that the SxIP (Ser-x-Ile-Pro) amino acid sequence is the major
EB1 binding motif in other EB1 interacting proteins, such as
APC and CLASP2 (62). Using the DILIMOT algorithm se-
quence analysis software (62), we identified a similar amino
acid sequence, Ser-x-x-Lys-Pro, in APC, AIM2, and ASC
(data no shown). Further studies using site-specific mutagen-
esis to disrupt the interaction site could help verify this po-
tential binding site. When an inflammasome receptor interacts
with a cytoplasmic pathogen, it undergoes a conformational
change that is important for its association with ASC and their
downstream targets (63). Based on our observation that the
interaction between EB1 and AIM2 was markedly increased
following poly (dA:dT) treatment in vitro (Fig. 3B), we specu-
late that AIM2 may undergo a conformational change after
interacting with cytoplasmic DNA, thereby exposing the EB1-
binding motif and facilitating this binding ability. We found
that the CT domain of EB1 is involved in the interactions with
AIM2 and ASC. The CT domain has been reported to recruit
the TIP complex to stabilize the plus ends of microtubules
(26). We found that the CH domain of EB1, which is the
microtubule-binding domain, could directly interact with AIM2
in vitro, but this association was weaker than that of the CT
domain with AIM2 in vivo (Fig. 4A). These observations sug-
gest that the CH domain has a higher binding affinity for
microtubules than for AIM2.
Although we herein show that EB1 is an AIM2 inflam-
masome-interacting protein that is required for speck-like
particle formation, the molecular mechanism through which
EB1 affects speck-like particle formation is not yet known.
Because EB1 regulates microtubule polymerization and re-
cruits the TIP complex to the plus end of the microtubule,
we speculate that EB1 may recruit the AIM2 inflammasome to
form the speck-like particle on the plus end of the microtu-
bule. EB1-mediated microtubule stabilization was reported to
be regulated by the small Rho GTPase, RhoA (28), and an-
other small Rho GTPase, Rac1, was shown to regulate inflam-
masome activation in macrophage (21). Our knockdown anal-
ysis of individual small GTPases in NPC cells showed that
poly (dA:dT)-induced, AIM2-mediated IL-1 secretion was
decreased by silencing of RhoA, but not Rac1 or cdc42 (sup-
plemental Fig. S6A). In addition, poly (dA:dT)-induced, AIM2-
mediated IL-1 secretion was significantly reduced in NPC
cells treated with the microtubule polymerization inhibitor,
nocodazole (supplemental Fig. S6B). In contrast, treatment of
these cells with paclitaxel, which stabilizes microtubule po-
lymerization, slightly increased AIM2-mediated IL-1 secre-
tion (supplemental Fig. S5B). Thus, we propose that AIM2
inflammasome activation may depend on plus-end microtu-
bule polymerization, and cytoskeletal regulation may affect
inflammasome activation by mediating complex formation.
Indeed, a report showed that the NLRP3 inflammasome was
constitutively activated without ligand stimulation in meta-
static melanoma cells, but not in primary melanoma cells (64),
possibly suggesting that cytoskeletal rearrangement may par-
ticipate in inflammasome activation. Collectively, our findings
link microtubule stabilization to AIM2 inflammasome activa-
tion. Further investigation of AIM2 inflammasome activation
in other cell types subjected to knockdown of various small
Rho GTPases may clarify whether specific small GTPases
are required for inflammasome activation via stabilization of
EB1.
Because inflammasomes are important for defense against
pathogens infection in immune cells, here, we showed that
EB1 is the novel component in inflammasome complex and
important for their activation in NPC cells. EB1 was reported
to be up-regulated during macrophage activation in THP-1
cells (60), and knockdown of EB1 significantly reduced IL-l
secretion (p  0.05) and caspase 1 activation in THP-1 cells
after poly (dA:dT) treatment (supplemental Fig. S7), suggest-
ing that EB1 is also involved in AIM2 inflammasome activation
in immune cells.
FIG. 6. Correlation of EB1 expression with AIM2 and ASC in NPC patients. Immunohistochemical staining of EB1, AIM2, and ASC were
detected by specific antibodies in consecutive NPC tissue sections from three NPC patients. The results are shown at 200magnification (left,
scale bar  200 m) and 400 magnification (right, scale bar  100 m).
TABLE III
The correlation of EB1 expression with AIM2 or ASC in NPC patients
AIM2 ASC
Level High Low p value High Low p value
EB1 High 40 13 p  0.05 32 21 p  0.001
Low 23 19 10 32
EB1 is the Novel Component of Activated Inflammasome
1242 Molecular & Cellular Proteomics 11.11
The elevated expression of EB1 and its strong correlation
with AIM2 and ASC expression in NPC tumor cells suggest
that our findings are of strong physiological relevance. We
previously noted that ASC and AIM2 are independent prog-
nostic biomarkers capable of predicting better local recur-
rence-free survival of patients under current treatment re-
gimes (unpublished data). EB1 has been reported as a
biomarker for many cancers (54–56), so we may presume that
EB1 also serves as an NPC biomarker. Furthermore, increas-
ing evidence suggests that inflammation and inflammasome
activation are involved in cancer tumorigenesis (17, 46). Here,
we show for the first time that EB1 is important for inflam-
masome activation via microtubule stabilization. Thus, future
studies are warranted to test whether cytoskeletal integrity or
cell mobility activities could be targeted for the development
of new therapeutic strategies against inflammasome-derived
chronic inflammatory diseases.
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